Literature DB >> 16380619

Elevated IL-6 and TNF-alpha levels in patients with ALS: inflammation or hypoxia?

C Moreau1, D Devos, V Brunaud-Danel, L Defebvre, T Perez, A Destée, A B Tonnel, P Lassalle, N Just.   

Abstract

Abnormal levels of interleukin (IL)-6 were described in patients with ALS, related to an inflammatory process. The authors compared IL-6 and tumor necrosis factor alpha (TNF-alpha) levels in CSF and sera from 10 hypoxemics and 10 normoxemics patients with ALS to those of 10 hypoxemics and 10 normoxemics neurologic controls. The same pattern exists in patients with ALS and controls: the highest levels are found in hypoxic conditions and undetectable levels are found in normoxemic conditions. Elevated IL-6 levels in ALS could correspond to a normal response to hypoxemia.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16380619     DOI: 10.1212/01.wnl.0000188907.97339.76

Source DB:  PubMed          Journal:  Neurology        ISSN: 0028-3878            Impact factor:   9.910


  48 in total

1.  Alsin and SOD1(G93A) proteins regulate endosomal reactive oxygen species production by glial cells and proinflammatory pathways responsible for neurotoxicity.

Authors:  Qiang Li; Netanya Y Spencer; Nicholas J Pantazis; John F Engelhardt
Journal:  J Biol Chem       Date:  2011-09-20       Impact factor: 5.157

Review 2.  Targeting TNF-α to elucidate and ameliorate neuroinflammation in neurodegenerative diseases.

Authors:  Kathryn A Frankola; Nigel H Greig; Weiming Luo; David Tweedie
Journal:  CNS Neurol Disord Drug Targets       Date:  2011-05       Impact factor: 4.388

Review 3.  Peripheral inflammation in neurodegeneration.

Authors:  Ulrike Träger; Sarah J Tabrizi
Journal:  J Mol Med (Berl)       Date:  2013-04-02       Impact factor: 4.599

4.  HIV-1 Tat-induced microglial activation and neuronal damage is inhibited via CD45 modulation: A potential new treatment target for HAND.

Authors:  Jingji Jin; Lucy Lam; Edin Sadic; Frank Fernandez; Jun Tan; Brian Giunta
Journal:  Am J Transl Res       Date:  2012-07-22       Impact factor: 4.060

Review 5.  CSF markers in amyotrophic lateral sclerosis.

Authors:  Joanna Tarasiuk; Alina Kułakowska; Wiesław Drozdowski; Johannes Kornhuber; Piotr Lewczuk
Journal:  J Neural Transm (Vienna)       Date:  2012-05-04       Impact factor: 3.575

6.  Increased serum ferritin levels in amyotrophic lateral sclerosis (ALS) patients.

Authors:  E F Goodall; M S Haque; K E Morrison
Journal:  J Neurol       Date:  2008-07-18       Impact factor: 4.849

7.  Combined Metabolomics and Transcriptomics Approaches to Assess the IL-6 Blockade as a Therapeutic of ALS: Deleterious Alteration of Lipid Metabolism.

Authors:  Franck Patin; Thomas Baranek; Patrick Vourc'h; Lydie Nadal-Desbarats; Jean-François Goossens; Sylviane Marouillat; Anne-Frédérique Dessein; Amandine Descat; Blandine Madji Hounoum; Clément Bruno; Hervé Watier; Mustafa Si-Tahar; Samuel Leman; Jean-Claude Lecron; Christian R Andres; Philippe Corcia; Hélène Blasco
Journal:  Neurotherapeutics       Date:  2016-10       Impact factor: 7.620

8.  Efficacy of thalidomide for the treatment of amyotrophic lateral sclerosis: a phase II open label clinical trial.

Authors:  Elijah W Stommel; Jeffrey A Cohen; Camilo E Fadul; Christopher H Cogbill; David J Graber; Linda Kingman; Todd Mackenzie; Jacqueline Y Channon Smith; Brent T Harris
Journal:  Amyotroph Lateral Scler       Date:  2009 Oct-Dec

Review 9.  Vitamin D as a potential therapy in amyotrophic lateral sclerosis.

Authors:  Alexandro Gianforcaro; Mazen J Hamadeh
Journal:  CNS Neurosci Ther       Date:  2014-02       Impact factor: 5.243

10.  Lenalidomide (Revlimid) administration at symptom onset is neuroprotective in a mouse model of amyotrophic lateral sclerosis.

Authors:  Arie Neymotin; Susanne Petri; Noel Y Calingasan; Elizabeth Wille; Peter Schafer; Charles Stewart; Kenneth Hensley; M Flint Beal; Mahmoud Kiaei
Journal:  Exp Neurol       Date:  2009-09-04       Impact factor: 5.330

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.